Entering text into the input field will update the search result below

HUMA Humacyte, Inc.
Stock Price & Overview

$2.84-0.02 (-0.70%)3:59 PM 09/26/23
NASDAQ | $USD | Post-Market: $2.93 +0.09 (+3.17%) 7:34 PM

Charts

FFO (FWD)
PE
Div Rate (TTM)
Yield (TTM)
Short Interest
Market Cap
Volume
Prev. Close

Quant Ranking

Ratings Summary

Now6M ago
SA Analysts
Not CoveredRating: Not Covered
Wall Street
Not CoveredRating: Not Covered
Quant
Not CoveredRating: Not Covered

Ratings Summary

SA Analysts
Wall Street
Quant
Now3M ago6M ago
Valuation
-Rating: Not Covered
Growth
-Rating: Not Covered
Profitability
-Rating: Not Covered
Momentum
-Rating: Not Covered
Revisions
-Rating: Not Covered

See HUMA ratings with Premium.

Company Profile

Humacyte, Inc. logo
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
Employees
164
Founded
2004
Address
  • 2525 East North Carolina Highway 54
  • Durham, NC, 27713
  • United States
Phone Number
919 313 9633
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.